S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer

• Sponsor: National Cancer Institute (NCI) (NIH)
• Overall Status: Completed
• CT.gov ID: NCT00368992
• Collaborator: (none)
• Enrollment: 110
• Location: 1
• Arm: 1
• Duration (Months): 50
• Patients Per Site Per Month: 2.2

Study Details

Study Description

Brief Summary

Monoclonal antibodies, such as cetuximab and bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Cetuximab may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab may stop the growth of tumor cells by blocking blood flow to the tumor. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving cetuximab together with paclitaxel, carboplatin, and bevacizumab may kill more tumor cells. This phase II trial is studying how well giving cetuximab together with paclitaxel, carboplatin, and bevacizumab works in treating patients with advanced non-small cell lung cancer

Condition or Disease	Intervention/Treatment	Phase
Adenocarcinoma of the Lung; Adenosquamous Cell Lung Cancer; Bronchoalveolar Cell Lung Cancer; Large Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer	Biological: cetuximab; Drug: paclitaxel; Biological: bevacizumab	Phase 2

Detailed Description

PRIMARY OBJECTIVES:

1. To evaluate the frequency and severity of hemorrhage toxicities in patients with advanced non-small cell lung cancer treated with the combination of carboplatin, paclitaxel, cetuximab and bevacizumab followed by therapy with cetuximab and bevacizumab.

SECONDARY OBJECTIVES:

1. To evaluate progression-free and overall survival, response rate (confirmed plus unconfirmed, complete plus partial), and frequency and severity of non-hemorrhage toxicities in this group of patients treated with this regimen.

2. To perform molecular correlative studies on patient tissue to investigate in an exploratory manner potential predictors of efficacy.

OUTLINE: This is a multicenter study.

INDUCTION THERAPY: Patients receive cetuximab IV over 1-2 hours on days 1, 8, and 15 and paclitaxel IV over 3 hours, carboplatin IV over 30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.

MAINTENANCE THERAPY: Patients receive cetuximab IV over 1 hour on days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed every 3 months for 1 year and then every 6 months for up to 3 years.

Study Design

• Study Type: Interventional
• Actual Enrollment: 110 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase II Trial of Combination Carboplatin, Paclitaxel, Cetuximab and Bevacizumab (NSC-704865) Followed By Cetuximab and Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer
• Study Start Date: Aug 1, 2006
• Actual Primary Completion Date: Oct 1, 2010
• Actual Study Completion Date: Oct 1, 2010

Arms and Interventions

Arm

Intervention/Treatment

Experimental: Treatment (cetuximab, paclitaxel, bevacizumab) INDUCTION THERAPY: Patients receive cetuximab IV over 1-2 hours on days 1, 8, and 15 and paclitaxel IV over 3 hours, carboplatin IV over 30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. MAINTENANCE THERAPY: Patients receive cetuximab IV over 1 hour on days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.

Biological: cetuximab; Given IV; Other Names: C225 C225 monoclonal antibody IMC-C225 MOAB C225 monoclonal antibody C225 ; Drug: paclitaxel; Given IV; Other Names: Anzatax Asotax TAX Taxol ; Biological: bevacizumab; Given IV; Other Names: anti-VEGF humanized monoclonal antibody anti-VEGF monoclonal antibody Avastin rhuMAb VEGF

Outcome Measures

Primary Outcome Measures

1. The Percentage of Patients With Grade 4 (i.e. Life-threatening) Hemorrhage Toxicities Related to Protocol Treatment. [Every week until removed from protocol therapy, up to 3 years.]

   All patients who received protocol treatment were assessed for adverse events per the NCI Common Terminology Criteria for Adverse Events, Version 3.0. We counted the number of patients who reported at least one Grade 4 (i.e. life-threatening) hemorrhage adverse event that was possibly, probably, or definitely related to the study treatment.

Secondary Outcome Measures

1. Progression-Free Survival [Every 6 weeks until disease progression. After 9 months, every 12 weeks until disease progression, up to 3 years.]

   From data of registration to date of disease progression (as defined by RECIST, i.e. a 20% increase in the sum of the longest diameters of target lesions, or unequivocal progression ina non-target lesion in the opinion of the treating investigator, or the appearance of new lesions), symptomatic deterioration, or death due to any cause. Patients last known to be alive and progression-free were censored at the date of last contact.

2. Overall Survival [Once a week, up to 3 years.]

   From date of enrollment to date of death due to any cause. Patients last known to be alive were censored at date of last contact.

3. Response Rate [Every 6 weeks while on protocol treatment, up to 3 years.]

   Confirmed and unconfirmed complete and partial responses per RECIST in the subset of patients with at least one target lesion assessed by CT or MRI. A complete response (CR) was defined as disappearance of all disease, including non-target lesions. A partial response (PR) was defined as a >= 30% decrease in the sum of the longest diameters of all target lesions. A CR or PR was confirmed if documented a second time at least 4 weeks after the first documentation.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Patients must have histologically or cytologically proven newly diagnosed selected stage IIIB (T4 lesion due to malignant pleural effusion) or stage IV, advanced primary non-small cell lung cancer (adenocarcinoma, large cell carcinoma, or unspecified) or recurrent disease after previous surgery and/or irradiation; patients with tumors having squamous cell components > 50% are not eligible

• Patients with known brain metastases are not eligible; all patients must have a pretreatment CT or MRI scan of the brain to evaluate for CNS disease within 42 days prior to registration

• Patients may have measurable or non-measurable disease documented by CT, MRI, X-ray or physical exam; measurable disease must be assessed within 28 days prior to registration; pleural effusions, ascites and laboratory parameters are not acceptable as the only evidence of disease; non-measurable disease must be assessed within 42 days prior to registration; all disease must be assessed and documented on the Baseline Tumor Assessment Form (Form #848)

• Patients must not have received any prior systemic chemotherapy or biologic therapy for non-small cell lung cancer; patients must not have received any adjuvant therapy for non-small cell lung cancer

• Prior radiation is permitted; however, at least three weeks must have elapsed since the completion of prior radiation therapy and patients must have recovered from all associated toxicities at time of registration; measurable or non-measurable disease must be outside the previous radiation field or a new lesion must be present

• At least four weeks must have elapsed since surgery (thoracic or other major surgeries) and patients must have recovered from all associated toxicities at the time of registration; measurable disease must be present outside the area of surgical resection; there must be no anticipation of need for major surgical procedures during protocol treatment

• Patients must not have received prior cetuximab, ZD1839, erlotinib or other investigational agents that target the EGFR pathway; patients must not have received prior VEGF-related agents; patients must not have received prior chimerized or murine monoclonal antibody therapy or have documented presence of human anti-mouse antibodies (HAMA)

• ANC >= 1,500/mcl

• Platelet count >= 100,000/mcl

• Hemoglobin >= 9 mg/dl

• Patients must have a serum creatinine =< institutional upper limit of normal (IULN) AND calculated or measured creatinine clearance >= 50 cc/min using the Cockroft-Gault Formula

• Urine protein must be screened by urine analysis for Urine Protein Creatinine (UPC) ratio; for UPC ratio > 0.5, 24-hour urine protein must be obtained and the level must be < 1,000 mg for patient enrollment

• Serum bilirubin =< 2 x IULN

• Either SGOT or SGPT =< 2 x IULN (if both SGOT and SGPT are done, both must be =< 2 x IULN)

• International Normalized Ratio (INR) =< 1.5; patients must not be taking full-dose anticoagulation therapy; patients may be enrolled initially if they are on low-dose warfarin (i.e., 1 mg daily)

• All patients must have a Zubrod performance status of 0 - 1

• Correlative science studies: institutions must have received IRB approval of S9925 (the Lung Cancer Specimen Repository); patients must be offered participation in S9925; with the patient's consent, blood, plasma and tissue will be submitted for testing via S9925; patients must be registered separately to S9925 in order for institutions to receive credit for specimen submissions

• Patients must not have had hemoptysis >= 1/2 teaspoon within 3 months prior to registration

• Patients must not have >= grade 2 symptomatic neuropathy-sensory (National Cancer Institute [NCI] Common Terminology Criteria Version 3.0)

• Patients must not have documented evidence of acute hepatitis or have an active or uncontrolled infection

• Patients must not have the following: history (within past 6 months) of CVA, myocardial infarction or unstable angina; uncontrolled hypertension; New York Heart Association grade 2 or greater congestive heart failure; serious cardiac arrhythmia requiring medication; or clinically significant peripheral vascular disease

• Patients must not have had an open biopsy or significant traumatic injury within 28 days prior to registration; patients must not have had a core biopsy within 7 days prior to registration

• Patients must not have serious or non-healing wound, ulcer or bone fracture

• Patients must not have history of abdominal fistula, gastrointestinal perforation or intraabdominal abscess within 28 days prior to registration

• Patients must have no known hypersensitivity of Chinese hamster ovary cell products or other recombinant human antibodies

• Patients must not have evidence of bleeding diathesis or coagulopathy

• Patients must be willing to provide prior smoking history as required on the S0536 Prestudy Form (Form #54655)

• No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for 5 years

• Pregnant or nursing women are not eligible for this trial; women/men of reproductive potential must not participate unless they have agreed to use an effective contraceptive method during protocol treatment and for at least 6 months following completion of bevacizumab treatment

• Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines

• At the time of patient registration, the treating institution's name and ID number must be provided to the Data Operations Center in Seattle in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered into the data base

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Southwest Oncology Group	San Antonio	Texas	United States	78245

Sponsors and Collaborators

• National Cancer Institute (NCI)

Investigators

• Principal Investigator: Edward Kim, Southwest Oncology Group

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: National Cancer Institute (NCI)
• ClinicalTrials.gov Identifier: NCT00368992
• Other Study ID Numbers: NCI-2012-02903; S0536; U10CA032102
• First Posted: Aug 29, 2006
• Last Update Posted: Sep 14, 2015
• Last Verified: Feb 1, 2013

• Additional relevant MeSH terms: Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma of Lung; Adenocarcinoma, Bronchiolo-Alveolar; Paclitaxel; Bevacizumab; Cetuximab; Antineoplastic Agents, Immunological; Antibodies; Immunoglobulins; Antibodies, Monoclonal

Study Results

Participant Flow

Arm/Group Title	Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab
Arm/Group Description	This was a single arm Phase II trial. Patients were treated with induction therapy cetuximab IV over 1-2 hours on days 1, 8, and 15 and paclitaxel IV over 3 hours, carboplatin IV over 30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who were not removed due to unacceptable toxicity or disease progression were then treated with maintenance therapy cetuximab IV over 1 hour on days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
Period Title: Overall Study
STARTED	110
COMPLETED	0
NOT COMPLETED	110

Baseline Characteristics

Arm/Group Title	Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab
Arm/Group Description	This was a single arm Phase II trial. Patients were treated until progression.
Overall Participants	102
Age (years) [Median (Full Range) ]
Median (Full Range) [years]	64
Sex: Female, Male (Count of Participants)
Female	50 49%
Male	52 51%

Outcome Measures

1. Primary Outcome

Title	The Percentage of Patients With Grade 4 (i.e. Life-threatening) Hemorrhage Toxicities Related to Protocol Treatment.
Description	All patients who received protocol treatment were assessed for adverse events per the NCI Common Terminology Criteria for Adverse Events, Version 3.0. We counted the number of patients who reported at least one Grade 4 (i.e. life-threatening) hemorrhage adverse event that was possibly, probably, or definitely related to the study treatment.
Time Frame	Every week until removed from protocol therapy, up to 3 years.

Outcome Measure Data

Analysis Population Description

Eligible patients who received protocol treatment were included in the analysis.

Arm/Group Title	Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab
Arm/Group Description
Measure Participants	102
Number (95% Confidence Interval) [percentage of participants]	2 2%

2. Secondary Outcome

Title	Progression-Free Survival
Description	From data of registration to date of disease progression (as defined by RECIST, i.e. a 20% increase in the sum of the longest diameters of target lesions, or unequivocal progression ina non-target lesion in the opinion of the treating investigator, or the appearance of new lesions), symptomatic deterioration, or death due to any cause. Patients last known to be alive and progression-free were censored at the date of last contact.
Time Frame	Every 6 weeks until disease progression. After 9 months, every 12 weeks until disease progression, up to 3 years.

Outcome Measure Data

Analysis Population Description

Eligible patients who received protocol treatment were included in the analysis.

Arm/Group Title	Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab
Arm/Group Description	This was a single arm Phase II trial. Patients were treated until progression.
Measure Participants	102
Median (95% Confidence Interval) [Months]	7

3. Secondary Outcome

Title	Overall Survival
Description	From date of enrollment to date of death due to any cause. Patients last known to be alive were censored at date of last contact.
Time Frame	Once a week, up to 3 years.

Outcome Measure Data

Analysis Population Description

Eligible patients who received protocol treatment were included in the analysis.

Arm/Group Title	Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab
Arm/Group Description	This was a single arm Phase II trial. Patients were treated until progression.
Measure Participants	102
Median (95% Confidence Interval) [months]	15

4. Secondary Outcome

Title	Response Rate
Description	Confirmed and unconfirmed complete and partial responses per RECIST in the subset of patients with at least one target lesion assessed by CT or MRI. A complete response (CR) was defined as disappearance of all disease, including non-target lesions. A partial response (PR) was defined as a >= 30% decrease in the sum of the longest diameters of all target lesions. A CR or PR was confirmed if documented a second time at least 4 weeks after the first documentation.
Time Frame	Every 6 weeks while on protocol treatment, up to 3 years.

Outcome Measure Data

Analysis Population Description

Eligible patients who received protocol treatment and who had measurable disease (as defined by RECIST) at baseline were included in the analysis.

Arm/Group Title	Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab
Arm/Group Description
Measure Participants	95
Number (95% Confidence Interval) [percentage of participants]	56 54.9%

Adverse Events

Time Frame	Weekly while on protocol treatment.
Arm/Group Title	Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab
Arm/Group Description
All Cause Mortality
	Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab
	Affected / at Risk (%)	# Events
Total	/ (NaN)
Serious Adverse Events
	Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab
	Affected / at Risk (%)	# Events
Total	51/102 (50%)
Blood and lymphatic system disorders
Febrile neutropenia	5/102 (4.9%)
Hemoglobin	1/102 (1%)
Cardiac disorders
Cardiac-ischemia/infarction	1/102 (1%)
Left ventricular diastolic dysfunction	1/102 (1%)
Left ventricular systolic dysfunction	1/102 (1%)
Ventricular arrhythmia - Ventricular tachycardia	1/102 (1%)
Eye disorders
Ocular/Visual-Other (Specify)	1/102 (1%)
Gastrointestinal disorders
Constipation	2/102 (2%)
Diarrhea	2/102 (2%)
Gastritis (including bile reflux gastritis)	1/102 (1%)
Mucositis/stomatitis (clinical exam) - Oral cavity	2/102 (2%)
Nausea	5/102 (4.9%)
Obstruction, GI - Small bowel NOS	1/102 (1%)
Pain - Abdomen NOS	1/102 (1%)
Vomiting	2/102 (2%)
General disorders
Death not associated with CTCAE term - Death NOS	2/102 (2%)
Fatigue (asthenia, lethargy, malaise)	6/102 (5.9%)
Sudden death	1/102 (1%)
Immune system disorders
Cytokine release syndrome/acute infusion reaction	1/102 (1%)
Infections and infestations
Inf (clin/microbio) w/Gr 3-4 neuts - Blood	1/102 (1%)
Inf (clin/microbio) w/Gr 3-4 neuts - Colon	1/102 (1%)
Inf (clin/microbio) w/Gr 3-4 neuts - Lung	4/102 (3.9%)
Inf (clin/microbio) w/Gr 3-4 neuts - Sinus	1/102 (1%)
Inf (clin/microbio) w/Gr 3-4 neuts - UTI	1/102 (1%)
Inf w/normal ANC or Gr 1-2 neutrophils - Blood	1/102 (1%)
Inf w/normal ANC or Gr 1-2 neutrophils - Joint	1/102 (1%)
Inf w/normal ANC or Gr 1-2 neutrophils - Lung	3/102 (2.9%)
Inf w/normal ANC or Gr 1-2 neutrophils - Mid ear	1/102 (1%)
Infection with unknown ANC - Blood	1/102 (1%)
Investigations
Leukocytes (total WBC)	3/102 (2.9%)
Lymphopenia	1/102 (1%)
Neutrophils/granulocytes (ANC/AGC)	16/102 (15.7%)
Platelets	2/102 (2%)
Metabolism and nutrition disorders
Albumin, serum-low (hypoalbuminemia)	1/102 (1%)
Anorexia	3/102 (2.9%)
Dehydration	7/102 (6.9%)
Magnesium, serum-low (hypomagnesemia)	2/102 (2%)
Potassium, serum-low (hypokalemia)	2/102 (2%)
Sodium, serum-low (hyponatremia)	1/102 (1%)
Musculoskeletal and connective tissue disorders
Muscle weakness, not d/t neuropathy - body/general	3/102 (2.9%)
Musculoskeletal/Soft Tissue-Other (Specify)	1/102 (1%)
Pain - Back	2/102 (2%)
Pain - Buttock	1/102 (1%)
Pain - Chest wall	1/102 (1%)
Pain - Joint	2/102 (2%)
Pain - Muscle	1/102 (1%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Death - Disease progression NOS	3/102 (2.9%)
Nervous system disorders
CNS cerebrovascular ischemia	1/102 (1%)
Neuropathy: motor	1/102 (1%)
Neuropathy: sensory	1/102 (1%)
Ocular/Visual-Other (Specify)	1/102 (1%)
Seizure	1/102 (1%)
Syncope (fainting)	2/102 (2%)
Reproductive system and breast disorders
Vaginitis (not due to infection)	1/102 (1%)
Respiratory, thoracic and mediastinal disorders
Dyspnea (shortness of breath)	9/102 (8.8%)
Hemorrhage, pulmonary/upper respiratory - Lung	2/102 (2%)
Hypoxia	3/102 (2.9%)
Pain - Pleura	1/102 (1%)
Pleural effusion (non-malignant)	1/102 (1%)
Pneumonitis/pulmonary infiltrates	4/102 (3.9%)
Pneumothorax	2/102 (2%)
Skin and subcutaneous tissue disorders
Rash/desquamation	2/102 (2%)
Vascular disorders
Hypertension	1/102 (1%)
Hypotension	2/102 (2%)
Phlebitis (including superficial thrombosis)	1/102 (1%)
Thrombosis/thrombus/embolism	7/102 (6.9%)
Other (Not Including Serious) Adverse Events
	Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab
	Affected / at Risk (%)	# Events
Total	101/102 (99%)
Blood and lymphatic system disorders
Hemoglobin	58/102 (56.9%)
Eye disorders
Vision-blurred vision	6/102 (5.9%)
Gastrointestinal disorders
Constipation	57/102 (55.9%)
Diarrhea	45/102 (44.1%)
Dysphagia (difficulty swallowing)	7/102 (6.9%)
Heartburn/dyspepsia	15/102 (14.7%)
Mucositis/stomatitis (clinical exam) - Oral cavity	36/102 (35.3%)
Mucositis/stomatitis (functional/symp) - Oral cav	21/102 (20.6%)
Nausea	53/102 (52%)
Pain - Abdomen NOS	11/102 (10.8%)
Pain - Oral cavity	6/102 (5.9%)
Vomiting	25/102 (24.5%)
General disorders
Edema: limb	10/102 (9.8%)
Fatigue (asthenia, lethargy, malaise)	88/102 (86.3%)
Pain - Chest/thorax NOS	10/102 (9.8%)
Pain-Other (Specify)	14/102 (13.7%)
Rigors/chills	6/102 (5.9%)
Immune system disorders
Allergic reaction/hypersensitivity	14/102 (13.7%)
Infections and infestations
Inf w/normal ANC or Gr 1-2 neutrophils - UTI	11/102 (10.8%)
Infection-Other (Specify)	8/102 (7.8%)
Investigations
ALT, SGPT (serum glutamic pyruvic transaminase)	22/102 (21.6%)
AST, SGOT	22/102 (21.6%)
Alkaline phosphatase	31/102 (30.4%)
Bilirubin (hyperbilirubinemia)	8/102 (7.8%)
Creatinine	6/102 (5.9%)
Leukocytes (total WBC)	52/102 (51%)
Lymphopenia	9/102 (8.8%)
Metabolic/Laboratory-Other (Specify)	6/102 (5.9%)
Neutrophils/granulocytes (ANC/AGC)	62/102 (60.8%)
Platelets	40/102 (39.2%)
Weight loss	40/102 (39.2%)
Metabolism and nutrition disorders
Albumin, serum-low (hypoalbuminemia)	30/102 (29.4%)
Anorexia	43/102 (42.2%)
Calcium, serum-low (hypocalcemia)	31/102 (30.4%)
Dehydration	17/102 (16.7%)
Glucose, serum-high (hyperglycemia)	56/102 (54.9%)
Glucose, serum-low (hypoglycemia)	11/102 (10.8%)
Magnesium, serum-low (hypomagnesemia)	50/102 (49%)
Potassium, serum-high (hyperkalemia)	11/102 (10.8%)
Potassium, serum-low (hypokalemia)	21/102 (20.6%)
Sodium, serum-low (hyponatremia)	29/102 (28.4%)
Musculoskeletal and connective tissue disorders
Muscle weakness, not d/t neuropathy - Extrem-lower	8/102 (7.8%)
Muscle weakness, not d/t neuropathy - body/general	14/102 (13.7%)
Pain - Back	19/102 (18.6%)
Pain - Bone	17/102 (16.7%)
Pain - Chest wall	9/102 (8.8%)
Pain - Extremity-limb	20/102 (19.6%)
Pain - Joint	32/102 (31.4%)
Pain - Muscle	24/102 (23.5%)
Nervous system disorders
Dizziness	21/102 (20.6%)
Neuropathy: motor	11/102 (10.8%)
Neuropathy: sensory	76/102 (74.5%)
Pain - Head/headache	13/102 (12.7%)
Taste alteration (dysgeusia)	25/102 (24.5%)
Psychiatric disorders
Insomnia	19/102 (18.6%)
Mood alteration - anxiety	15/102 (14.7%)
Mood alteration - depression	19/102 (18.6%)
Renal and urinary disorders
Proteinuria	13/102 (12.7%)
Respiratory, thoracic and mediastinal disorders
Allergic rhinitis	10/102 (9.8%)
Cough	27/102 (26.5%)
Dyspnea (shortness of breath)	44/102 (43.1%)
Hemorrhage, pulmonary/upper respiratory - Nose	27/102 (26.5%)
Mucositis/stomatitis (functional/symp) - Pharynx	7/102 (6.9%)
Nasal cavity/paranasal sinus reactions	8/102 (7.8%)
Voice changes/dysarthria	21/102 (20.6%)
Skin and subcutaneous tissue disorders
Dermatology/Skin-Other (Specify)	16/102 (15.7%)
Dry skin	26/102 (25.5%)
Hair loss/Alopecia (scalp or body)	50/102 (49%)
Nail changes	6/102 (5.9%)
Pruritus/itching	22/102 (21.6%)
Rash/desquamation	31/102 (30.4%)
Rash: acne/acneiform	78/102 (76.5%)
Rash: hand-foot skin reaction	9/102 (8.8%)
Vascular disorders
Hypertension	25/102 (24.5%)
Hypotension	12/102 (11.8%)

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.